Logo image of RNAZ

TRANSCODE THERAPEUTICS INC (RNAZ) Stock Fundamental Analysis

NASDAQ:RNAZ - Nasdaq - US89357L3033 - Common Stock - Currency: USD

9.86  -1.51 (-13.28%)

After market: 10.02 +0.16 (+1.62%)

Fundamental Rating

2

Taking everything into account, RNAZ scores 2 out of 10 in our fundamental rating. RNAZ was compared to 572 industry peers in the Biotechnology industry. While RNAZ seems to be doing ok healthwise, there are quite some concerns on its profitability. RNAZ has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RNAZ has reported negative net income.
RNAZ had a negative operating cash flow in the past year.
RNAZ had negative earnings in each of the past 5 years.
In the past 5 years RNAZ always reported negative operating cash flow.
RNAZ Yearly Net Income VS EBIT VS OCF VS FCFRNAZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

RNAZ's Return On Assets of -204.75% is on the low side compared to the rest of the industry. RNAZ is outperformed by 90.80% of its industry peers.
The Return On Equity of RNAZ (-325.62%) is worse than 76.28% of its industry peers.
Industry RankSector Rank
ROA -204.75%
ROE -325.62%
ROIC N/A
ROA(3y)-206.68%
ROA(5y)-227.97%
ROE(3y)-568.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNAZ Yearly ROA, ROE, ROICRNAZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

1.3 Margins

RNAZ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNAZ Yearly Profit, Operating, Gross MarginsRNAZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, RNAZ has more shares outstanding
RNAZ has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RNAZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RNAZ Yearly Shares OutstandingRNAZ Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 200K 400K 600K
RNAZ Yearly Total Debt VS Total AssetsRNAZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

RNAZ has an Altman-Z score of -14.20. This is a bad value and indicates that RNAZ is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -14.20, RNAZ is not doing good in the industry: 81.24% of the companies in the same industry are doing better.
RNAZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.2
ROIC/WACCN/A
WACCN/A
RNAZ Yearly LT Debt VS Equity VS FCFRNAZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 2.48 indicates that RNAZ has no problem at all paying its short term obligations.
RNAZ has a Current ratio of 2.48. This is in the lower half of the industry: RNAZ underperforms 71.50% of its industry peers.
A Quick Ratio of 2.48 indicates that RNAZ has no problem at all paying its short term obligations.
RNAZ has a Quick ratio of 2.48. This is in the lower half of the industry: RNAZ underperforms 70.44% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 2.48
RNAZ Yearly Current Assets VS Current LiabilitesRNAZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

RNAZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.26%, which is quite impressive.
EPS 1Y (TTM)95.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RNAZ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.87% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.94%
EPS Next 2Y41.4%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RNAZ Yearly Revenue VS EstimatesRNAZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M 50M
RNAZ Yearly EPS VS EstimatesRNAZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -10K -20K -30K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RNAZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RNAZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNAZ Price Earnings VS Forward Price EarningsRNAZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNAZ Per share dataRNAZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

RNAZ's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.4%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RNAZ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSCODE THERAPEUTICS INC

NASDAQ:RNAZ (2/7/2025, 8:00:01 PM)

After market: 10.02 +0.16 (+1.62%)

9.86

-1.51 (-13.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners11.46%
Inst Owner Change-19.73%
Ins Owners0.01%
Ins Owner Change0%
Market Cap5.13M
Analysts82.86
Price Target20.4 (106.9%)
Short Float %15.56%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.14%
Min EPS beat(2)-21.7%
Max EPS beat(2)67.99%
EPS beat(4)2
Avg EPS beat(4)-9.17%
Min EPS beat(4)-107.33%
Max EPS beat(4)67.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-83.33%
EPS NQ rev (1m)-970%
EPS NQ rev (3m)-723.08%
EPS NY rev (1m)92.16%
EPS NY rev (3m)-131.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-40%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.12
P/tB 1.12
EV/EBITDA N/A
EPS(TTM)-69.7
EYN/A
EPS(NY)-4.46
Fwd EYN/A
FCF(TTM)-30.53
FCFYN/A
OCF(TTM)-30.49
OCFYN/A
SpS0
BVpS8.82
TBVpS8.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -204.75%
ROE -325.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-206.68%
ROA(5y)-227.97%
ROE(3y)-568.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 2.48
Altman-Z -14.2
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)243.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.14%
EPS Next Y99.94%
EPS Next 2Y41.4%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.81%
OCF growth 3YN/A
OCF growth 5YN/A